ABEONA THERAPEUTICS INC. Deferred Revenue, Revenue Recognized
ABEONA THERAPEUTICS INC. (ABEO) reported Deferred Revenue, Revenue Recognized of $2.60 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2018-05-10
- ABEONA THERAPEUTICS INC. deferred revenue, revenue recognized for the quarter ending 2018-03-31 was $2.60M.
| Period end | Deferred Revenue, Revenue Recognized 3 month |
|---|---|
| 2018-03-31 | $2.60M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |